Co-Authors
This is a "connection" page, showing publications co-authored by Daniele Focosi and Massimo Franchini.
Connection Strength
5.157
-
Potential use of convalescent plasma for SARS-CoV-2 prophylaxis and treatment in immunocompromised and vulnerable populations. Expert Rev Vaccines. 2021 May 27; 1-8.
Score: 0.948
-
Clinical predictors of SARS-CoV-2 neutralizing antibody titers in COVID-19 convalescents: Implications for convalescent plasma donor recruitment. Eur J Haematol. 2021 Jul; 107(1):24-28.
Score: 0.941
-
COVID-19 convalescent plasma therapy: hit fast, hit hard! Vox Sang. 2021 10; 116(9):935-942.
Score: 0.938
-
The Road towards Polyclonal Anti-SARS-CoV-2 Immunoglobulins (Hyperimmune Serum) for Passive Immunization in COVID-19. Life (Basel). 2021 Feb 15; 11(2).
Score: 0.930
-
COVID-19 neutralizing antibody-based therapies in humoral immune deficiencies: A narrative review. Transfus Apher Sci. 2021 Jun; 60(3):103071.
Score: 0.926
-
COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors. Viruses. 2021 08 11; 13(8).
Score: 0.240
-
Patient-blood management for COVID19 convalescent plasma therapy: relevance of affinity and donor-recipient differences in concentration of neutralizing antibodies. Clin Microbiol Infect. 2021 Jul; 27(7):987-992.
Score: 0.235